3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Fluorouracil
8
Oxaliplatin
7
Surveys and Questionnaires
6
Leucovorin
6
Blood Specimen Collection
6
Specimen Handling
5
Gemcitabine
5
Cetuximab
5
Capecitabine
5
Bevacizumab
5
fludarabine
4
aldesleukin
4
Standard of Care
4
Cyclophosphamide
4
Remote Patient Monitoring
3
Radiosurgery
3
Pafolacianine
3
Nivolumab
3
Irinotecan
3
Endoscopic Mucosal Resection
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
encorafenib
2
Tomography, X-Ray Computed
2
Sunitinib
2
Referral and Consultation
2
Radiotherapy
2
Practice Guidelines as Topic
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
abelacimab
×
1 year
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled